GlassScriptPhysician profile
Adam R Davis
NPI 1043514011
$6,938.34
in general payments reported to CMS, 2019-2025
32 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,101 · 2020: $506 · 2021: $724 · 2022: $1,346 · 2023: $1,110 · 2024: $1,107 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,261.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $666.21 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $638.67 | 2019-2024 | Xarelto |
| Pfizer INC. | $607.80 | 2019-2025 | |
| Abbott Laboratories | $538.51 | 2019-2022 | |
| Amgen INC. | $423.05 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $378.52 | 2019-2024 | |
| Boston Scientific Corporation | $362.74 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Merck Sharp & Dohme LLC | $347.79 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.99 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $313.02 | 2019-2022 | |
| Astellas Pharma US INC | $255.48 | 2019-2023 | Lexiscan |
| Novo Nordisk INC | $250.96 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $212.20 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $209.68 | 2021-2025 | Eliquis, Camzyos |
| Philips North America LLC | $183.18 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $169.73 | 2019-2024 | Evkeeza |
| Astrazeneca Pharmaceuticals LP | $138.36 | 2019-2025 | Wainua, Farxiga |
| Masimo Corporation | $107.19 | 2023 | Set and Rainbow Set |
| Irhythm Technologies, INC. | $106.91 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Esperion Therapeutics, INC. | $103.90 | 2020-2024 | Nexletol |
| Atricure, INC. | $99.40 | 2019 | |
| Scpharmaceuticals INC. | $79.08 | 2024-2025 | |
| Tactile Systems Technology INC | $73.33 | 2020-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Kowa Pharmaceuticals America, INC. | $62.03 | 2019-2023 | Livalo |
| Baxter Healthcare | $56.47 | 2024 | Hillrom - Connex Spot Monitor, Hillrom - Carnation Ambulatory Monitor |
| Kiniksa Pharmaceuticals International, Plc | $52.60 | 2024 | Arcalyst |
| Angiodynamics, INC. | $40.17 | 2024 | Auryon Laser System 100-120 Vac |
| Lilly USA, LLC | $37.14 | 2025 | Zepbound |
| Bardy Diagnostics, INC. | $33.00 | 2021 | |
| Inspire Medical Systems, INC. | $24.54 | 2024 | Inspire |
| Glaxosmithkline, LLC. | $24.15 | 2025 | Arexvy, Shingrix |
| Medtronic, INC. | $19.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.